ATG7 and chronic myelogenous leukemia, BCR-ABL1 positive: Given the detrimental effect of Atg7 deletion in HSC in mouse models31 and in an attempt to anticipate possible myelosuppression in the clinic for the combination of TKI with specific autophagy inhibition, we assessed the effect of ATG7 knockdown on primary human non-CML CD34+ cells.